COP1 Deficiency in BRAFV600E Melanomas Confers Resistance to Inhibitors of the MAPK Pathway
Cells · 2025
DOI: 10.3390/cells14130975 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Ada Ndoja und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiological Chemistry, Genentech, South San Francisco, CA 94080, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Melanoma, Drug Resistance, Neoplasm, MAP Kinase Signaling System. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aberrant activation of the mitogen-activated protein kinase (MAPK) cascade promotes oncogenic transcriptomes. Despite efforts to inhibit oncogenic kinases, such as BRAFV600E, tumor responses in patients can be heterogeneous and limited by drug resistance mechanisms. Here, we describe patient tumors that acquired COP1 or DET1 mutations after treatment with the BRAFV600E inhibitor vemurafenib. COP1 and DET1 constitute the substrate adaptor of the E3 ubiquitin ligase CRL4COP1/DET1, which targets transcription factors, including ETV1, ETV4, and ETV5, for proteasomal degradation. MAPK-MEK-ERK signaling prevents CRL4COP1/DET1 from ubiquitinating ETV1, ETV4, and ETV5, but the mechanistic details are still being elucidated. We found that patient mutations in COP1 or DET1 inactivated CRL4COP1/DET1 in melanoma cells, stabilized ETV1, ETV4, and ETV5, and conferred resistance to inhibitors of the MAPK pathway. ETV5, in particular, enhanced cell survival and was found to promote the expression of the pro-survival gene BCL2A1. Indeed, the deletion of pro-survival BCL2A1 re-sensitized COP1 mutant cells to vemurafenib treatment. These observations indicate that the post-translational regulation of ETV5 by CRL4COP1/DET1 modulates transcriptional outputs in ERK-dependent cancers, and its inactivation contributes to therapeutic resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiological Chemistry, Genentech, South San Francisco, CA 94080, USA.
- Department of Neuroscience, Genentech, South San Francisco, CA 94080, USA.
- Department of Proteomics and Genomics Technologies, Genentech, South San Francisco, CA 94080, USA.
- Department of Molecular Oncology, Genentech, South San Francisco, CA 94080, USA.
- Department of Computational Sciences, Genentech, South San Francisco, CA 94080, USA.
- Melanoma Institute Australia, Wollstonecraft, NSW 2065, Australia.
ORCID-Profile: Ada Ndoja, Sarah Kummerfeld, Helen Rizos, Vishva M Dixit
Zitieren
APA
Ndoja, A., Rose, C. M., Lin, E., Reja, R., Petrovic, J., Kummerfeld, S., Blair, A., Rizos, H., Modrusan, Z., Martin, S., Kirkpatrick, D. S., Heidersbach, A., Sun, T., Haley, B., Karayel, O., Newton, K., & Dixit, V. M. (2025). COP1 Deficiency in BRAFV600E Melanomas Confers Resistance to Inhibitors of the MAPK Pathway. Cells. https://doi.org/10.3390/cells14130975
Vancouver
Ndoja A, Rose CM, Lin E, Reja R, Petrovic J, Kummerfeld S, et al. COP1 Deficiency in BRAFV600E Melanomas Confers Resistance to Inhibitors of the MAPK Pathway. Cells. 2025. doi:10.3390/cells14130975
BibTeX
@article{Ndoja2025,
author = {Ndoja, Ada and Rose, Christopher M and Lin, Eva and Reja, Rohit and Petrovic, Jelena and Kummerfeld, Sarah and Blair, Andrew and Rizos, Helen and Modrusan, Zora and Martin, Scott and Kirkpatrick, Donald S and Heidersbach, Amy and Sun, Tao and Haley, Benjamin and Karayel, Ozge and Newton, Kim and Dixit, Vishva M},
title = {COP1 Deficiency in BRAFV600E Melanomas Confers Resistance to Inhibitors of the MAPK Pathway},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14130975}
}
EUVIMED